Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation
Open Access
- 1 January 2025
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 703-714
Abstract
The bimatoprost intracameral implant (Durysta®) offers a sustained-release approach to glaucoma management, providing consistent intraocular pressure (IOP) reduction over several months and reducing the need for daily topical therapies. This review evaluates its pharmacology, efficacy, and safety, using data from pivotal clinical trials and recent real-world studies. The implant achieves IOP reductions comparable to topical prostaglandin analogs, with benefits for patient adherence and fewer common side effects. However, repeat administrations are associated with adverse effects such as endothelial cell loss, highlighting the need for optimized re-dosing schedules. Future research should explore its use in advanced glaucomas, cost-effectiveness, and combination with other IOP-lowering treatments. The bimatoprost intracameral implant represents a promising innovation in glaucoma therapy with potential for improved patient outcomes.Keywords
This publication has 46 references indexed in Scilit:
- Effect of bimatoprost sustained-release intracameral implant on intraocular pressure and medication burden in patients with prior glaucoma surgeryJournal Français d'Ophtalmologie, 2023
- Single Administration of Bimatoprost ImplantOphthalmology Glaucoma, 2023
- Updates on the Diagnosis and Management of GlaucomaMayo Clinic Proceedings: Innovations, Quality & Outcomes, 2022
- Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular HypertensionOphthalmology and Therapy, 2022
- Bimatoprost Implant: First ApprovalDrugs & Aging, 2020
- 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma PatientsDrugs, 2019
- Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical TrialAmerican Journal of Ophthalmology, 2017
- Glaucoma: The ‘Black hole’ of irreversible blindnessMedical Journal Armed Forces India, 2016
- Factors for Glaucoma Progression and the Effect of TreatmentArchives of Ophthalmology (1950), 2003
- The Ocular Hypertension Treatment StudyArchives of Ophthalmology (1950), 2002